

## **Shionogi participates in the Global Health Innovative Technology Fund**

---

**Osaka, Japan, April 8, 2013** - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it is participating in Japan’s first public-private partnership “Global Health Innovative Technology Fund” (hereafter “GHIT Fund”) to advance the research and development of innovative medicines for the treatment of infectious diseases in the developing world.

The GHIT Fund will fund and facilitate partnerships among Japanese pharmaceutical companies, universities and research institutions to create innovative medicines for the treatment of infectious diseases in developing countries. The fund also aims to advance and strengthen Japan’s contribution to global health.

Shionogi has been dedicated to providing innovative medicines for the treatment of infectious diseases, and will continue to focus on this therapeutic area to offer the greatest possible contribution to improving the lives of patients suffering from infectious diseases. Shionogi’s participation in the GHIT Fund is also expected to strengthen the healthcare and the quality of patient treatment in developing countries.

Shionogi strives constantly to accomplish its mission to provide innovative medicines to patients all over the world, and the GHIT Fund is a new, and important, element of that overall mission.

### **About the Global Health Innovative Technology Fund (GHIT Fund)**

The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization aimed to advance the research and development (R&D) of new health technologies from Japan to fight infectious diseases prevalent specifically in the developing world, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases (NTDs). Established as a public-private partnership between the Government of Japan, a consortium of pharmaceutical companies and the Bill & Melinda Gates Foundation, the GHIT Fund facilitates and funds the R&D of new health technologies through partnership creation and grant-making activities. To learn more about GHIT Fund, please see [www.ghitfund.org](http://www.ghitfund.org).

**Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**For further information, contact:**

Corporate Communications Department  
Shionogi & Co., Ltd.

Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596

Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099

**For further information about GHIT Fund:**

PR office (COSMO PR) Contact person: Maruan El Mahgiub

Global Health Innovative Technology Fund

Telephone: +81-3-5561-2915 Fax: +81-3-5561-2912 Email: [press@ghitfund.org](mailto:press@ghitfund.org)